Adult Clinical Trials

Lung Cancer

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact the Lung/ Thoracic Clinical Trials Office at 919.681.4768.

17 trials identified.

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide.
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Thoracic Oncology Research Office
Phone: 919.681.4768
Reference Number: 00007332
View this trial at ClinicalTrials.gov

A Phase 1 / 2 Multicenter Study of BMS-986012 in Subjects with Relapsed/Refractory Small Cell Lung Cancer
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Neal Ready
Contact: Thoracic Oncology Research Clinical Trials Office
Phone: 919.681.4768
Reference Number: 00056092
View this trial at ClinicalTrials.gov

SWOG S1400: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Thoracic Oncology Research Office
Phone: 919.681.4768
Reference Number: 00057165
View this trial at ClinicalTrials.gov

Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Phase: N/A
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Thoracic Oncology Research Office
Phone: 919.681.4768
Reference Number: 00057971
View this trial at ClinicalTrials.gov

Alliance A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Thoracic Oncology Research Office
Phone: 919.681.4768
Reference Number: 00057973
View this trial at ClinicalTrials.gov

ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Thoracic Oncology Research Office
Phone: 919.681.4768
Reference Number: 00060199
View this trial at ClinicalTrials.gov

A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A Anti-PD-L1 antibody) in Combination with Carboplatin + Nab-Paclitaxel for chemotherapy-Naive Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Jeffrey Clarke
Contact: Thoracic Oncology Research Clinical Trials Office
Phone: 919.681.4768
Reference Number: 00062549
View this trial at ClinicalTrials.gov

A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Thoracic Oncology Research Clinical Trials Office
Phone: 919.681.4768
Reference Number: 00062555
View this trial at ClinicalTrials.gov

An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY).
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Neal Ready
Contact: Thoracic Oncology Clinical Trials Office
Phone: 919.681.4768
Reference Number: 00069666
View this trial at ClinicalTrials.gov

An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Neal Ready
Contact: Thoracic Oncology Research Clinical Trials Office
Phone: 919.681.4768
Reference Number: 00069822
View this trial at ClinicalTrials.gov

A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Neal Ready
Contact: Thoracic Oncology Clinical Trials Office
Phone: 919.681.4768
Reference Number: 00070704
View this trial at ClinicalTrials.gov

Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Phase: Phase II
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Neal Ready
Contact: Thoracic Oncology Clinical Trials Office
Phone: 919.681.4768
Reference Number: 00071629
View this trial at ClinicalTrials.gov

Duke Thoracic, Head and Neck Biomarkers and Epidemiology Study
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Qingyi Wei
Contact: Epidemiology Oncology Research Team
Phone: 919.668.5691
Reference Number: 00072532

EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Thoracic Oncology Clinical Trials Office
Phone: 919.681.4768
Reference Number: 00073268
View this trial at ClinicalTrials.gov

Phase II trial of brigatinib after treatment with second-generation ALK inhibitors in refractory ALK rearranged NSCLC
Phase: Phase II
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Thomas Stinchcombe
Contact: Thoracic Oncology Clinical Trials Office
Phone: 919.681.4768
Reference Number: 00074492
View this trial at ClinicalTrials.gov

A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in participants with Non-Small Cell Lung Cancer
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Neal Ready
Contact: Thoracic Oncology Clinical Trials Office
Phone: 919.681.4768
Reference Number: 00075721
View this trial at ClinicalTrials.gov

Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Thomas Stinchcombe
Contact: Thoracic Oncology Clinical Trials Office
Phone: 919.681.4768
Reference Number: 00076665